Eli Lilly beats Q2 estimates on strong sales growth
Eli Lilly (LLY) reported Q2 earnings per share of $6.31, well above the $5.59 expected. Revenue came in at $15.56 B, exceeding forecasts of $14.67 B, driven by robust demand for its diabetes and weight-loss drugs. The company’s market capitalization now stands at $561.67 B.
